La Jolla Pharmaceutical Company (LJPC)
LJPCPrice: $6.19
Fair Value: 🔒
🔒score
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive sh... more
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that i... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | George Tidmarsh |
| IPO Date | 1994-06-03 | CAGR | 0.2% |
| Employees | 61 | Website | www.lajollapharmaceutical.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LJPC chart loading...
Fundamentals
Technicals
| Enterprise Value | $54.23M | P/E Ratio | 47.62 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -3.17 |
| P/CF Ratio | 7.49 | P/FCF Ratio | — |
| EPS | $0.13 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -33.79% | Gross Margin | 0.82% |
| Operating Margin | 0.29% | Profit Margin | 0.26% |
| ROE | -0.25% | ROA | 0.19% |
| ROCE | 0.26% | Current Ratio | 3.82 |
| Quick Ratio | 3.46 | Cash Ratio | 2.65 |
| Debt/Equity | -0.04 | Interest Coverage | 2.09 |
| Altman Z Score | — | Piotroski Score | — |